IGT 427
Alternative Names: IGT-427Latest Information Update: 12 Dec 2023
At a glance
- Originator INGENIA Therapeutics
- Class Bispecific antibodies; Eye disorder therapies
- Mechanism of Action TIE-2 receptor agonists; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic macular oedema; Wet age-related macular degeneration
Most Recent Events
- 24 Oct 2023 Ingenia Therapeutics plans a phase phase I trial for Diabetic macular oedema in Q2 of 2024 (Ingenia Therapeutics pipeline, Octorber 2023)
- 24 Oct 2023 Ingenia Therapeutics plans a phase phase I trial for Wet age-related macular degeneration in Q2 of 2024 (Ingenia Therapeutics pipeline, Octorber 2023)
- 02 May 2022 Ingenia Therapeutics enters into a strategic collaboration with Mosaic Biosciences to optimize Ingenia’s protein therapeutics for improved drug properties